Okamura T, Nanno S, Sueishi K, Tanaka K
Acta Pathol Jpn. 1984 Jul;34(4):749-57. doi: 10.1111/j.1440-1827.1984.tb07603.x.
Fibrinolytic inhibitor was prepared from human aortas and some of its biochemical properties were investigated. The fibrinolytic inhibitor suppressed urokinase activity, but did not inhibit plasmin activity when assayed by fibrin plate method and synthetic fluorogenic substrate method. The urokinase inhibitor was a glycoprotein and migrated similar to alpha-globulin upon fibrin-agar electrophoresis. The molecular weight determined by gel filtration was approximately 98,000. The urokinase inhibitor was immunologically different from other known plasma protease inhibitors, such as alpha 2-plasmin inhibitor, alpha 2-macroglobulin, and alpha 2-antitrypsin. The interaction of urokinase with the inhibitor was dose-dependent. Progressive inactivation of urokinase occurred by increasing time of incubation with the inhibitor at 37 degrees C, and over 90% inhibition of urokinase required 30 min of incubation. The inhibitor of plasminogen activator in human aorta may be noteworthy in relation to thrombogenesis and atherogenesis.
从人主动脉制备了纤维蛋白溶解抑制剂,并对其一些生化特性进行了研究。当通过纤维蛋白平板法和合成荧光底物法测定时,该纤维蛋白溶解抑制剂抑制尿激酶活性,但不抑制纤溶酶活性。尿激酶抑制剂是一种糖蛋白,在纤维蛋白 - 琼脂电泳中迁移情况与α - 球蛋白相似。通过凝胶过滤测定的分子量约为98,000。尿激酶抑制剂在免疫方面与其他已知的血浆蛋白酶抑制剂不同,如α2 - 纤溶酶抑制剂、α2 - 巨球蛋白和α2 - 抗胰蛋白酶。尿激酶与抑制剂的相互作用呈剂量依赖性。在37℃下,随着与抑制剂孵育时间的增加,尿激酶会逐渐失活,超过90%抑制尿激酶需要30分钟的孵育时间。人主动脉中纤溶酶原激活剂的抑制剂在血栓形成和动脉粥样硬化形成方面可能值得关注。